HCM
CADL icon

Heights Capital Management’s Candel Therapeutics CADL Stock Holding History

Heights Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.8M Buy
+775,000
New +$4.22M 1.06% 20
2025
Q1 		– Sell
-30,000
Closed -$260K – 132
2024
Q4 		$260K Buy
+30,000
New +$177K 0.13% 55

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Heights Capital Management's CADL Position: Q1 2026 in Review

Heights Capital Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 775,000 shares worth $3.8M. The stake represents 1.06% of the portfolio and ranks #20 among its holdings. This is a return to the name: Heights Capital Management previously reported a position in CADL as recently as Q4 2024.

Heights Capital Management first reported a position in CADL in Q4 2024 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Heights Capital Management held 775,000 shares of Candel Therapeutics worth $3.8M as of Q1 2026.
  • Candel Therapeutics was a new Heights Capital Management position in Q1 2026.
  • Candel Therapeutics made up 1.06% of Heights Capital Management's portfolio in Q1 2026, its #20 holding.
  • Heights Capital Management first reported a position in Candel Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Heights Capital Management's 13F filing for Q1 2026, filed 15 May 2026.